Evaluation of the Effects of vitamin D3 supplementation on Irritable bowel syndrome symptoms.

Evaluation of The Effects of vitamin D3 supplementation on Irritable bowel syndrome symptoms

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201402234010N11

Enrollment

Registered

2014-04-04

Start date

2013-02-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrome. Irritable bowel syndrome

Interventions

Intervention 1: Intervention 1: In intervention group: - oral vitamin D3 (50000IU), one per week, for 2 months. classifying Intervention: drug intervention using drug. Intervention 2: Intervention

Treatment - Drugs

Placebo

Intervention 1: In intervention group: - oral vitamin D3 (50000IU), one per week, for 2 months. classifying Intervention: drug intervention using drug.

Intervention 2: In placebo group: capsules containing rice flour (placebo), one per week for 2 months. - classifying intervention: intervention with placebo.

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age between 18 to 65 years old; serum level of 25(OH)D under 30 ng/ml; evidence of having irritable bowel syndrome using Rome III Criteria; not having Vitamin D supplementation since one year ago; not having a history of alcohol drink; not suffering from other organic diseases of the intestine, bowel surgery, breast; cancer, severe mental illness; not pregnant, breastfeeding and professional sports; not taking Non-steroidal anti-inflammatory drug ( NSAIDs), laxatives, nicotine, artificial sweeteners, antibiotics, immunomodulators or repression, intestinal bleeding, drugs, fish oils and digestive movements modifier. Exclusion criteria: their unwillingness to continue the study for any reason; pregnancy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
25 (OH) D. Timepoint: before and after studu (end of second month). Method of measurement: ELISA.;Constipation. Timepoint: before and after study (end of second month). Method of measurement: question.;Diarrhea. Timepoint: before and after study (end of second month). Method of measurement: question.;Bloating and abdominal pain. Timepoint: before and after study (end of second month). Method of measurement: question.	—

Measure

Time frame

25 (OH) D. Timepoint: before and after studu (end of second month). Method of measurement: ELISA.;Constipation. Timepoint: before and after study (end of second month). Method of measurement: question.;Diarrhea. Timepoint: before and after study (end of second month). Method of measurement: question.;Bloating and abdominal pain. Timepoint: before and after study (end of second month). Method of measurement: question.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Azita Hekmatdoost

National Nutrition and Food Technology Research Institute (NNFTRI)

a_hekmat2000@yahoo.com+98 21 2235 7484

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 22, 2026